Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercepharma.com
FiercePharma
Get the latest updates from FiercePharma directly as they happen.
Follow now 403 followers
Latest posts
Last updated 18 minutes ago
Avalyn heads to Nasdaq with oversized $300M IPO to fund reformulated respiratory drugs
18 minutes ago
Avalyn Pharma has overshot its expectations with a $300 million IPO that...
US drugmaker’s reputations shift quickly amid political pressures, job cuts: survey
about 4 hours ago
Patient groups’ perceptions of drugmakers with large U.S. footprints have shifted in...
With Austedo at helm, Teva's impressive innovative drug sales signal company's successful metamorphosis
about 14 hours ago
While Teva Pharmaceutical’s multiyear growth streak under CEO Richard Francis showed signs...
AstraZeneca CEO's conservative MFN model excludes reference markets from forecast
about 14 hours ago
As AstraZeneca braces for the impact of the U.S. “most favored nation”...
AbbVie outlines Skyrizi defense against new J&J plaque psoriasis rival Icotyde
about 14 hours ago
Immunology med Skyrizi charted sales growth of 30.9% over 2026's first quarter...
Regeneron's quarterly sales of Eylea drop below $1B for the first time in 8 years
about 17 hours ago
As regulatory delays continue to plague Regeneron's Eylea franchise, quarterly sales for...
New GSK CEO’s first quarter boosted by Shingrix surge as Exdensur stumbles in switch trial
about 18 hours ago
In GSK’s first quarter with Luke Miels as CEO, the company’s flagship...
Pfizer looks to jump start Elrexfio with topline win in second-line myeloma
about 19 hours ago
With a new positive trial readout, the company is aiming to reach...
AstraZeneca restarts $300M investment in UK, but Merck not budging
about 19 hours ago
AstraZeneca has announced it will resume a $300 million investment program in...
Chiesi lays out $1.9B to bolster rare disease offerings with KalVista buyout
about 19 hours ago
As Ekterly nears the one-year anniversary of its approval, Chiesi Group is...
Novartis CEO calls for 'complete rethink' of Europe's drug pricing policies
1 day ago
Novartis CEO Vas Narasimhan says that Europe needs a “complete rethink” on...
Pfizer’s victory in delaying Vyndamax generics is mixed bag for BridgeBio: analysts
1 day ago
Pfizer now anticipates its Vyndamax sales to remain “relatively stable” from 2028...